Abstract. ABT-737, a BH3-mimetic small-molecule inhibitor, binds with very high affinity to Bcl-2, Bcl-xL and Bcl-w, and inhibits their activity. Aurora kinase is one of the serine/threonine kinase family members and is a vital and critical regulator of mitosis and meiosis. In the present study, we investigated the effects and mechanisms of a combined treatment of ABT-737 and VX-680 (Aurora kinase inhibitor) in human breast cancer MDA-MB-435S cells. ABT-737 plus VX-680 induced caspase-dependent apoptosis in the human breast cancer cells. Combined treatment with ABT-737 and VX-680 led to the downregulation of Bcl-2 expression at the transcriptional level and the downregulation of c-FLIP and Mcl-1 expression at the post-transcriptional level. Overexpression of Bcl-2 or c-FLIP could not block the induction of apoptosis caused by the combined treatment with ABT-737 and VX-680. However, overexpression of Mcl-1 partially inhibited the induction of apoptosis. In contrast, the combined treatment with ABT-737 and VX680 had no effect on the apoptosis in normal cells. Taken together, our study demonstrated that combined treatment with ABT-737 and VX-680 induced apoptosis in anti-apoptotic protein (Bcl-2 or c-FLIP)-overexpressing cells.
Introduction
The Bcl-2 superfamily of proteins is classified based on function and Bcl-2 homology (BH)-domain organization, such as anti-apoptotic, pro-apoptotic and BH3-only proteins. Anti-apoptotic Bcl-2 proteins maintain mitochondrial outer membrane permeability by binding to Bax and Bak; thus, overexpression of Bcl-2 results in apoptosis resistance in tumors (1) . In contrast, pro-apoptotic Bcl-2 proteins increase mitochondrial outer membrane permeabilization (MOMP), which is related to induction of apoptosis. BH3-only proteins are classified into 2 groups: activators and sensitizers. Activator BH3-only proteins, such as Bid, Bim, and Puma, bind to anti-and pro-apoptotic proteins, whereas sensitizer BH3-only proteins, such as Noxa, bind to anti-apoptotic proteins. When anti-apoptotic proteins bind to BH3-only proteins, activator BH3-only proteins and pro-apoptotic proteins induce MOMP, resulting in the induction of apoptosis (2, 3) . ABT-737 is a small-molecule BH3 mimetic, and directly binds to Bcl-2, Bcl-xL and Bcl-w with a very high affinity, resulted in induction of apoptosis by releasing Bax and Bak. Therefore, ABT-737 induces apoptosis in several types of cancer cells, such as leukemia, myeloma and small-cell lung cancer cells (4) (5) (6) . In contrast, since ABT-737 has a very low affinity for Mcl-1 (7, 8) , several types of cancer cells are resistant to ABT-737. Therefore, to enhance the sensitivity of ABT-737, a strategy of combined treatment is needed.
Aurora kinases are serine/threonine kinases, and are important for cell proliferation, cell cycle regulation, mitotic spindle formation, centrosome maturation, and cytokinesis (9, 10) . Aurora kinase is divided into 3 groups: A, B, and C. Both Aurora kinase A and B are expressed in most normal cells, while Aurora kinase C is only expressed in testicular tissue (11) . Recently, several studies found that Aurora kinases are overexpressed in tumors, and the extent of Aurora kinase overexpression is correlated with malignancy and poor prognosis (12) (13) (14) . Therefore, Aurora kinases are important therapeutic targets. These molecular-targeted strategies inhibit specific molecules, which vary between cancer and normal cells. However, these strategies could be safer and more effective.
In the present study, we investigated whether a combined treatment with ABT-737 and an Aurora kinase inhibitor induces apoptosis, and we aimed to identify the mechanism involved in the combined treatment-mediated apoptosis in human breast carcinoma MDA-MB-435S cells. VO 4 , and 1 µM NaF) containing protease inhibitors (100 µM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml pepstatin and 2 µM EDTA). The lysates were centrifuged at 10,000 x g for 10 min at 4˚C, and the supernatant fractions were collected. The proteins were separated by SDS-PAGE and transferred to an Immobilon-P membrane. The specific proteins were detected using an enhanced chemiluminescence (ECL) western blotting kit according to the manufacturer's instructions.
Materials and methods

Cells
Cell death assessment by DNA fragmentation assays. A Cell Death Detection ELISA Plus kit (Boehringer Mannheim, uSA) was used for assessing apoptotic activity by detecting fragmented DNA within the nucleus in the ABT-737-, VX-680-, and combined ABT-737 and VX-680-treated cells. Briefly, each culture plate was centrifuged for 10 min at 200 x g, the supernatant was removed, and the pellet was lysed for 30 min. After centrifuging the plate again at 200 x g for 10 min, the supernatant that contained the cytoplasmic histone-associated DNA fragments was collected and incubated with an immobilized anti-histone antibody. The reaction products were incubated with a peroxidase substrate for 5 min and measured by spectrophotometry at 405 and 490 nm (reference wavelength) with a microplate reader. The signals in the wells containing the substrate alone were subtracted as the background.
Determination of synergy.
The possible synergistic effect of ABT-737 and VX-680 was evaluated using the isobologram method. Briefly, the cells were treated with different concentrations of ABT-737 and VX680 alone or in combination. After 48 h, relative survival was assessed and the concentration effect curves were used to determine the IC 50 (the half-maximal inhibitory concentration) values for each drug alone and in combination with a fixed concentration of the second agent (15) . DNA transfection and the luciferase assay. Transient transfection was performed in 6-well plates. One day before the transfection, MDA-MB-435S cells were plated at ~60-80% confluency. The Bcl-2/-3254 promoter-luciferase, NF-κB-luciferase, and cAMP response element (CRE)-luciferase plasmid were transfected into the cells using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, uSA). The NF-κB-luciferase (plasmid no. 26699) plasmid was purchased from Addgene (Cambridge, MA, uSA) (16) . The CRE-luciferase plasmid was purchased from Clontech (Palo Alto, CA, uSA). To assess the promoter-driven expression of the luciferase gene, the cells were collected and disrupted by sonication in lysis buffer (25 µM Tris-phosphate pH 7.8, 2 µM EDTA, 1% Triton X-100 and 10% glycerol), and aliquots of the supernatants were used to analyze the luciferase activity according to the manufacturer's instructions (Promega, Madison, WI, uSA).
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Statistical analysis. The data were analyzed using a one-way ANOVA followed by post-hoc comparisons (Student-Newman-Keuls) using the statistical package for Social Sciences version 22.0 (SPSS Inc., Chicago, IL, uSA).
Results
Combined treatment with ABT-737 and VX-680 induces apoptosis in breast carcinoma MDA-MB-435S cells.
Signaling molecule-target drugs inhibit specific signaling, which is different between cancer and normal cells, and a combination strategy reduces adverse effects, such as toxicity in normal cells. Therefore, we examined whether a combined treatment with sublethal dosages of ABT-737 and VX-680, which inhibits ATP-binding of Aurora kinase A, B and C (17), induces apoptosis in breast carcinoma MDA-MB-435S cells. ABT-737 plus VX-680 markedly induced cell shrinkage and membrane blebbing (Fig. 1A) . To determine whether ABT-737 plus VX-680 induces apoptosis, FACS analysis to measure the DNA content and western blotting to detect the cleavage of PARP, a substrate of caspase-3, were performed. VX-680 induced G2/M arrest, but had no effect on apoptosis. However, the combined treatment with ABT-737 and VX-680 increased the sub-G1 population and PARP cleavage (Fig. 1B) . In addition, ABT-737 plus VX-680 markedly increased cytoplasmic histone-associated DNA fragmentation (Fig. 1C) . Next, to investigate whether the combined treatment with ABT-737 and VX-680 has a synergistic effect, MDA-MB-435S cells were treated with varied concentrations of ABT-737 and VX-680. The isobologram analysis revealed that the combined treatment with ABT-737 and VX-680 had synergistic effects (Fig. 1D) . Next, to determine whether caspase is involved in the ABT-737 and VX-680-induced apoptosis, we examined caspase activity. ABT-737 and VX-680 increased caspase-3 activity, and a general caspase inhibitor, z-VAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone) markedly reduced apoptosis and PARP cleavage ( Fig. 1E and F) . These data revealed that the combined treatment with ABT-737 and VX-680 induced caspase-dependent apoptosis in the breast carcinoma MDA-MB-435S cells.
Effect of ABT-737 plus VX-680 on other types of cancer cells and on normal cells. We investigated the effects of a combined treatment with ABT-737 and VX-680 on other types of cancer cells [human renal carcinoma (Caki cells), human lung carcinoma (A549 cells)] and normal cells (HSFs)].
Combined treatment with ABT-737 and VX-680 markedly induced apoptosis and PARP cleavage in the Caki and A549 cells ( Fig. 2A  and B) . When MDA-MB-435S cells were treated with ABT-737 plus VX-680, the cell morphology was altered including cellular shrinkage and blebbing, while the morphology of the HSFs was not altered (Fig. 2C) . Furthermore, combined treatment with ABT-737 and VX-680 had no effect on the sub-G1 population in the normal cells (Fig. 2C) . Therefore, our results indicate that the combined treatment of ABT-737 and VX-680 induced apoptosis in cancer cells, but not in normal cells.
Effect of ABT-737 plus VX-680 on apoptosis-related proteins.
Next, we investigated the expression levels of the Bcl-2 family, the inhibitor of apoptosis (IAP) family and death receptors in ABT-737 and VX-680-treated cells. As shown in Fig. 3A , ABT-737 and VX-680 alone had no effect on apoptosis-related proteins, while the combined treatment with ABT-737 and VX-680 reduced c-FLIP, Bcl-2 and Mcl-1 protein expression. Furthermore, downregulation of Bcl-2 mRNA was detected, while the mRNA expression levels of c-FLIP and
Mcl-2 were not altered in the ABT-737 plus VX-680-treated cells (Fig. 3B) . To further confirm the mechanism of Bcl-2 downregulation in ABT-737 plus VX-680-treated cells, we examined whether the combined treatment with ABT-737 and VX-680 inhibits Bcl-2 promoter activity. As shown in Fig. 3C , ABT-737 plus VX-680 markedly reduced Bcl-2 promoter (Bcl-2/-3254) activity. Furthermore, we investigated whether the combined treatment with ABT-737 plus VX-680 inhibits NF-κB and CRE-associated transcriptional activities, which are important to Bcl-2 mRNA expression (18) (19) (20) . NF-κB and CRE transcriptional activities were markedly reduced in the ABT-737 plus VX-680-treated cells (Fig. 3D) . These results indicated that NF-κB and CRE transcriptional activities are involved in ABT-737 plus VX-680-mediated downregulation of Bcl-2 expression. with ABT-737 and VX-680 induced apoptosis in the Bcl-2-or c-FLIP-overexpressed cells.
Effect of Bcl-2, c-FLIP and
Effect of inhibition of Aurora kinase A and B on apoptosis in VX-680-treated cells.
In the present study, we used VX-680, which inhibits both Aurora kinase A and B. To identify which Aurora kinase plays an important role in ABT-737-induced apoptosis, we tested more specific inhibitors of Aurora kinase A (MLN8237) and Aurora kinase B (barasertib). As shown in Fig. 5 , both inhibitors of Aurora kinase A (MLN8237) and Aurora kinase B (barasertib) induced an increase in the sub-G1 population and PARP cleavage in the ABT-737-treated cells ( Fig. 5A and B) . Therefore, these results revealed that inhibition of both Aurora kinase A and B could be involved in the apoptosis in ABT-737-treated cells.
Discussion
In Mcl-1 at the post-transcriptional level. Furthermore, ABT-737 plus VX-680 had no effect on the apoptosis of normal cells. Therefore, our results revealed that combined treatment with ABT-737 and VX-680 is an effective strategy to induce apoptosis in cancer cells.
In breast cancer cells, Aurora kinases are overexpressed, thus targeting to Aurora kinases is a good strategy by which to induce apoptosis. Pan-Aurora kinase inhibitor (VX-680) alone did not induce apoptosis, whereas VX-680 induced G2/M arrest (Fig. 1B) . Combined treatment with ABT-737 and VX-680 markedly induced apoptosis through caspase activation (Fig. 1E) . As shown in Fig. 3A , ABT-737 plus VX-680 markedly reduced c-FLIP, Bcl-2, and Mcl-1 protein expression. Firstly, downregulation of Bcl-2 is modulated at the transcriptional levels. Several transcription factors regulate Bcl-2 transcriptional level. Among them, p53 negatively modulates Bcl-2 expression (21-23). We investigated whether combined treatment with ABT-737 and VX-680 downregulates Bcl-2 mRNA by p53. However, pifithrin-α (p53 inhibitor) had no effect on the downregulation of ABT-737 plus VX-680-mediated Bcl-2 expression, and combined treatment with ABT-737 and VX-680 reduced Bcl-2 expression in wild-type p53 HCT116 human colon carcinoma cells and p53-null HCT116 cells (data not shown). Therefore, we ruled out the possibility of p53-mediated modulation. NF-κB and CRE are associated with Bcl-2 mRNA expression (18) (19) (20) . We found that combined treatment with ABT-737 and VX-680 markedly decreased NF-κB and CRE transcriptional activities (Fig. 3D) . These results indicate that the ABT-737 plus VX-680-mediated inhibition of NF-κB and CRE transcriptional activities is probably involved in the downregulation of Bcl-2 expression. Next, to identify the importance of Bcl-2 in ABT-737 plus VX-680-mediated apoptosis, MDA-MB-435S cells were transiently transfected with the Bcl-2 expression plasmid. As shown in Fig. 4B , although Bcl-2 was overexpressed, the combined treatment with ABT-737 plus VX-680 markedly induced apoptosis. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with a very high affinity, resulting in induction of apoptosis. ABT-737 inhibited the anti-apoptotic function of Bcl-2, thus the population of apoptotic cells was not changed. Secondly, ABT-737 plus VX-680 reduced Mcl-1 and c-FLIP expression at the post-transcriptional level. ubiquitin-dependent proteasomal degradation is a major mechanism of posttranscriptional regulation (24) , and Mcl-1 and c-FLIP are also mainly degraded by the ubiquitin-proteasome pathway. Therefore, further experiments are needed to identify the relationship of proteasome activation in the downregulation of Mcl-1 and c-FLIP. As shown in Fig. 4D , overexpression of Mcl-1 attenuated ABT-737 plus VX-680-induced apoptosis. Since ABT-737 has a low affinity for Mcl-1, Mcl-1-overexpressing cells are resistant to ABT-737-induced apoptosis. In contrast, when c-FLIP was overexpressed, ABT-737 plus VX-680 induced apoptosis (Fig. 4C) . Song et al, reported that ABT-737 (>5 µM) induces DR5 expression in renal carcinoma cells (25) . Induction of DR5 expression overcomes endogenous c-FLIP expression (25) . However, in the present study, ABT-737 did not induce DR5 expression (Fig. 3A) , while ABT-737 plus VX-680 induced apoptosis in the c-FLIP-overexpressing cells. Further experiments are needed to identify the mechanism of ABT-737 plus VX-680-mediated apoptosis in c-FLIP-overexpressing cells.
Taken together, our results revealed that the combination treatment with ABT-737 and VX-680 induced apoptosis in breast cancer cells, and overcame resistance by overexpression of Bcl-2 and c-FLIP.
